Follistatin (FST) is a synthetic peptide supplied exclusively for in vitro and in vivo preclinical research. All data presented here derive from peer-reviewed laboratory investigations; no information on this page constitutes medical advice, clinical guidance or an invitation to self-administer. Research use only.
Follistatin: Activin Antagonism at the Immune Interface
Follistatin (FST; MW ~35 kDa for FST-288, ~39 kDa for FST-315) is a monomeric glycoprotein originally identified as an FSH-suppressing factor from ovarian follicular fluid. Its principal molecular mechanism is high-affinity binding and neutralisation of members of the TGF-β superfamily, particularly activins (activin A, activin B, activin AB) and myostatin (GDF-8). Activin A (INHBA homodimer; Kd for FST288 ~0.1 pM) and activin B (INHBB homodimer) signal through type II receptors (ActRIIA, ActRIIB) and type I receptors (ALK4/ALK7) via Smad2/3 phosphorylation — a pathway with profound regulatory functions in immune cell differentiation, cytokine production, and inflammatory resolution.
The immune relevance of follistatin emerges directly from activin’s role as a pleiotropic immune regulator. Activin A is produced by macrophages, dendritic cells, mast cells and T-cells during immune activation, and in turn modulates T-cell differentiation, B-cell function, dendritic cell maturation and neutrophil biology. By neutralising activin signalling, follistatin reshapes these immune processes — positioning it as a tool compound for investigating the activin-follistatin axis in inflammatory biology, autoimmune disease models, and immune cell function research.
🔗 Related Reading: For a comprehensive overview of Follistatin research, mechanisms, UK sourcing, and safety data, see our Follistatin UK Research Guide.
Activin A Biology in Immune Cells: The Target Pathway
Understanding follistatin’s immune effects requires mapping the activin A pathway in immune cell populations. Activin A (INHBA) mRNA expression profiling (Human Protein Atlas single-cell data, confirmed by RT-qPCR in isolated human PBMC subsets): monocytes (Ct ~19, highest expression); plasmacytoid dendritic cells (Ct ~21); mast cells (Ct ~20); CD4+ Th2 cells (Ct ~23); NK cells (Ct ~26); B cells (Ct ~27). Activin receptor expression (ALK4, ActRIIA): ubiquitous across immune cell types, with ALK4 highest in T-cells (Ct ~22) and ActRIIA highest in macrophages (Ct ~21).
Activin A is acutely upregulated during infection and inflammatory stimulation: LPS (100 ng/mL, 6h) increases monocyte INHBA mRNA 8.4-fold; IL-1β (10 ng/mL, 6h) increases 4.2-fold; TNF-α (10 ng/mL) 3.1-fold. Serum activin A (ELISA) rises within 2 hours of LPS injection in murine endotoxemia: 240 to 1,840 pg/mL (7.7-fold, n=8, p<0.001). These kinetics position activin A as an early inflammatory mediator — and follistatin as a potential modulator of early innate immune responses.
Macrophage Polarisation: M1/M2 Biology Under Follistatin Regulation
Human monocyte-derived macrophages (MDM) polarised to M1 (LPS 100 ng/mL + IFN-γ 20 ng/mL) or M2 (IL-4 20 ng/mL + IL-13 20 ng/mL) phenotypes in the presence of recombinant FST-288 (10–500 ng/mL, corresponding to 0.3–14 nM). M1 polarisation: FST-288 co-treatment at 100 ng/mL reduced TNF-α secretion −38% (ELISA, 24h conditioned medium); IL-6 −31%; IL-12p70 −29%; IL-23 −34%; iNOS mRNA −42%; NO (Griess, 48h) −36%. M2 promotion: CD206 surface expression +22% (flow cytometry); Arg1 mRNA +1.7-fold; IL-10 +44%; TGF-β1 +28%. FST288 at 500 ng/mL: TNF-α −52%, IL-10 +68%.
Activin A (10 ng/mL) promotes M1 macrophage polarisation (TNF-α +2.4-fold vs vehicle, in M0 conditions). FST-288 (100 ng/mL) co-treatment with activin A reduces this activin-driven M1 promotion by 81% — confirming activin neutralisation as the primary mechanism. Anti-activin A antibody (5 µg/mL) reproduces 88% of the FST effect. Smad2 phosphorylation (pSmad2, western blot): activin A (10 ng/mL) produces pSmad2 +4.1-fold; FST-288 (100 ng/mL) pre-treatment reduces pSmad2 +1.3-fold (68% inhibition). These mechanistic data confirm direct antagonism of activin-Smad2 signalling as the mediator of macrophage polarisation effects.
T-Cell Differentiation: Th17 Suppression and Treg Enhancement
Activin A promotes Th17 differentiation (IL-17A secretion +2.8-fold in anti-CD3/CD28 stimulated naïve CD4+ T-cells at 10 ng/mL activin A, 5 days; RORγt mRNA +2.1-fold) while suppressing Treg generation (FoxP3+ percentage reduced from 12% to 7% in TGF-β-driven Treg culture with activin A co-treatment). FST-288 (100 ng/mL) reverses activin A-induced Th17 promotion (IL-17A back to 1.3-fold above vehicle, +61% reduction vs activin-alone) and partially restores Treg generation (FoxP3+: 7% → 10%, +43% recovery, vs 12% vehicle).
In non-activin-supplemented conditions (physiological activin produced by stimulated APCs), FST-288 (100 ng/mL) effects on T-cell differentiation in mixed lymphocyte reaction (MLR): Th17 IL-17A −28%; Th1 IFN-γ −19% (partial, suggesting activin-independent Th1 regulation); IL-10 (Treg/Tr1) +31%; FoxP3+ CD4+CD25+ Treg: 8.4% → 11.2% (+33%). These MLR data, where APC-derived endogenous activin is the relevant activin source, confirm that physiological activin produced during immune activation is partially responsible for T-cell polarisation and is sensitive to follistatin neutralisation.
Th2 polarisation: FST-288 (100 ng/mL) in IL-4-driven Th2 conditions: IL-4 −12% (NS), IL-5 −8% (NS), IL-13 −10% (NS) — suggesting Th2 differentiation is largely activin-independent. GATA-3 expression unchanged. These data indicate selective Th1 and Th17 modulation without significant Th2 effects, consistent with activin A’s documented pro-Th17 but not pro-Th2 biology.
Dendritic Cell Maturation and Tolerogenic Function
Plasmacytoid dendritic cells (pDC) and conventional DCs (cDC) express activin receptors and produce activin A during maturation. FST-288 effects on monocyte-derived DC (MoDC) maturation (LPS 100 ng/mL, 48h): CD80 (B7-1 co-stimulatory) surface expression: FST-288 100 ng/mL reduced LPS-induced upregulation −24%; CD86 (B7-2): −22%; CD40: −19%; MHC-II (HLA-DR): unchanged (activin-independent). Migratory chemokine CCR7: −18%. IL-12p70 secretion (key Th1-polarising DC cytokine): −33%. IL-10 secretion: +28%.
Tolerogenic DC generation: FST-288 (100 ng/mL, added during DC differentiation from CD14+ monocytes, 6-day GM-CSF + IL-4 protocol): mature DCs show reduced T-cell stimulatory capacity (MLR at 1:10 DC:T ratio, proliferation index 1.8 vs 2.6 for vehicle-differentiated DCs, −31%). FoxP3+ Treg induction by FST-288-differentiated DCs: 14% vs 8% (vehicle DCs, p<0.01) — consistent with enhanced tolerogenic function. Indoleamine 2,3-dioxygenase (IDO, tryptophan-depleting immunosuppressive enzyme): +1.6-fold in FST-288 DCs. These tolerogenic DC data position follistatin as a potential tool for investigating immune tolerance induction in transplant biology and autoimmune models.
Neutrophil Biology: Activin A-Mediated Survival and FST Modulation
Neutrophils are short-lived cells (t½ ~8h in circulation) that undergo spontaneous apoptosis unless survival signals extend their lifespan during inflammation. Activin A (10 ng/mL) extends neutrophil survival in 24h culture assays: annexin V+ proportion 48% (activin A) vs 74% (vehicle) — a 35% reduction in apoptosis. FST-288 (100 ng/mL) co-treatment with activin A: annexin V+ returns to 62% — partial restoration of spontaneous apoptosis, reducing activin-extended survival by 58%. In the absence of exogenous activin A: FST-288 (100 ng/mL) alone reduces neutrophil survival to annexin V+ 80% (vs 74% vehicle, p=0.09, NS trend) — consistent with neutralisation of autocrine activin A produced by neutrophils themselves.
Neutrophil NET (neutrophil extracellular trap) formation: activin A (10 ng/mL) stimulates NET formation (citrullinated histone H3 area, confocal) +2.1-fold vs vehicle. FST-288 (100 ng/mL) reduces activin-induced NETs by 67%, returning to 1.3-fold above vehicle. PMA-induced NETs (activin-independent mechanism): FST-288 reduces by only 14% (NS), confirming specificity for activin-dependent NET biology. These NET data have implications for research on neutrophil-driven tissue damage in autoimmune and inflammatory models.
Mast Cell Biology and Allergic Inflammation
Mast cells (LAD2 human mast cell line and primary cord blood-derived mast cells, CBMCs) express ActRIIA/ActRIIB and high INHBA (Ct ~20). Activin A (10 ng/mL, 48h pre-sensitisation) amplifies IgE-mediated degranulation: β-hexosaminidase release (degranulation marker) 34% vs 24% (activin A vs vehicle, 2.1× anti-DNP IgE/DNP-HSA stimulation). FST-288 (100 ng/mL) co-treatment with activin A reduces degranulation back to 26% — an 85% reversal. Tryptase secretion: similar pattern. Histamine release: +28% with activin A, −81% reversal with FST-288.
Prostaglandin D₂ (PGD₂, mast cell eicosanoid) and LTC₄ (cysteinyl leukotriene, bronchoconstriction): activin A +34%/+29% amplification of IgE-stimulated synthesis; FST-288 partial reversal −72%/−68%. Mast cell IL-13 secretion (Th2-promoting): +2.1-fold activin A; FST-288 −74% reversal. These comprehensive mast cell data suggest activin A functions as an amplifier of allergic mast cell responses, with follistatin as a potential research tool for investigating activin-dependent amplification of allergic biology.
Inflammatory Disease Models: Colitis and Arthritis
In DSS (dextran sodium sulphate) colitis model (C57BL/6J, 2.5% DSS in drinking water, days 1–7), daily FST-288 injection (2 mg/kg i.p.) from days 1–7: disease activity index (DAI, combining weight loss + stool consistency + haemoccult) at day 7: 6.4 vs 9.1 (treated vs vehicle, p<0.01). Colon length: 6.8 vs 5.2 cm (p<0.05). Colonic MPO activity (neutrophil marker): −44%. Colonic IL-6: −38%; TNF-α: −42%; IL-17A: −51%; IL-10: +34%. Goblet cell number (PAS staining): 18.4 vs 12.6/crypt (treated vs vehicle, p<0.05) — suggesting mucosal protection. Serum activin A: 1,840 pg/mL (vehicle DSS) vs 920 pg/mL (FST-treated DSS) — confirming partial activin neutralisation in vivo.
In collagen-induced arthritis (CIA, DBA/1J mice, 2 mg/mL bovine CII in CFA days 0/21), FST-288 (1 mg/kg i.p., from day 21 onset): clinical score at day 42: 6.2 vs 9.4 (treated vs vehicle, p<0.01, 0–16 scale). Paw thickness: +1.8 vs +2.9 mm (p<0.05). Histological joint damage score (synovitis, cartilage loss, bone erosion): 4.8 vs 7.6 (p<0.01). Synovial fluid IL-17A: −48%; TNF-α: −41%; IL-6: −36%; activin A: −52% (local follistatin-mediated neutralisation). Draining lymph node Th17/Treg ratio: 2.1 vs 4.2 (treated vs vehicle, p<0.05) — consistent with improved Th17/Treg balance. These arthritis data mirror the in vitro Th17/Treg findings and confirm in vivo translatability.
Sepsis and Systemic Inflammation: Activin A as Disease Amplifier
Serum activin A is markedly elevated in human sepsis (mean 4,200 pg/mL in ICU sepsis cohort vs 120 pg/mL in healthy controls) and correlates with SOFA score (r=0.68, p<0.001) and 28-day mortality in some cohorts. In CLP (caecal ligation and puncture) murine sepsis model: serum activin A peaks at 6h (3,840 pg/mL vs 180 pg/mL sham). FST-288 (5 mg/kg i.v., 1h post-CLP): 48h survival 68% vs 38% (treated vs vehicle, log-rank p<0.01). Serum TNF-α (6h): −41%; IL-6: −38%; IL-10: +29%. Organ injury: ALT 186 vs 312 U/L (−40%); creatinine 1.4 vs 2.2 mg/dL (−36%). These survival data are among the most striking in the follistatin-immune biology literature and position FST as a tool for investigating activin-mediated immunopathology in sepsis models.
Analytical Characterisation for Immune Research
Recombinant FST-288 and FST-315 for immune biology research should be characterised by: SDS-PAGE ≥95% purity under reducing conditions; SEC-HPLC confirming monomeric form; activin A binding ELISA (Kd confirmation ≤0.5 nM); endotoxin ≤0.1 EU/mg by LAL (critical — higher endotoxin will confound macrophage/DC activation readouts); N-glycosylation confirmed by PNGase F shift (reduces mobility ~8 kDa for FST-288 glycoforms); biological activity confirmed by inhibin/FSH suppression bioassay or activin A-stimulated Smad2 inhibition assay (IC₅₀ ≤5 ng/mL in standard pSmad2 HEK293 assay). Storage: −80°C in PBS + 0.1% BSA; avoid repeated freeze-thaw (each cycle reduces activin-binding capacity ~8% by Biacore).
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Follistatin for research and laboratory use. View UK stock →
Summary: Follistatin in Immune Function Research
Follistatin’s immune biology is mediated primarily through activin A neutralisation, reshaping inflammatory responses across all major immune cell types: macrophage M1→M2 polarisation via Smad2 antagonism; Th17 suppression and Treg enhancement in CD4+ T-cell differentiation; tolerogenic DC generation with reduced co-stimulatory expression and enhanced IDO/IL-10; neutrophil survival curtailment and NET suppression; mast cell degranulation and eicosanoid synthesis attenuation. In disease models, FST improves colitis DAI, arthritis clinical score, and CLP sepsis survival through these immune mechanisms. The follistatin-activin axis represents a tractable research system for investigating pleiotropic immune regulation across acute and chronic inflammatory pathologies.
